These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29164300)

  • 1.
    Rahbar K; Ahmadzadehfar H; Boegemann M
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):513-514. PubMed ID: 29164300
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
    Kim YJ; Kim YI
    Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Rahbar K; Bögemann M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):166-167. PubMed ID: 27699719
    [No Abstract]   [Full Text] [Related]  

  • 6. Exceptional 4-year response to
    Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
    Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PSMA radioligand therapy in patients with advanced prostate cancer].
    Bögemann M; Herrmann K; Radtke JP; Rahbar K
    Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
    Vatsa R; Sood A; Vadi SK; Das CK; Kaur K; Parmar M; Mittal BR
    Clin Nucl Med; 2020 Jun; 45(6):437-438. PubMed ID: 32366786
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sathekge M; Knoesen O; Meckel M; Modiselle M; Vorster M; Marx S
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1099-1100. PubMed ID: 28255795
    [No Abstract]   [Full Text] [Related]  

  • 11. Delayed response after repeated
    Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Boegemann M; Schrader AJ; Rahbar K
    Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer.
    Satapathy S; Das CK; Parihar AS; Sood A; Mittal BR
    Clin Nucl Med; 2021 Jul; 46(7):582-583. PubMed ID: 33630794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
    Wei X; Schlenkhoff C; Sopora C; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Nov; 41(11):894-895. PubMed ID: 27607162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
    Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
    Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
    Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S
    Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.